188O EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+/HER2− advanced or metastatic breast cancer (mBC) comparing oral elacestrant vs standard of care (SoC) endocrine therapy
| Autor: | Cortés, J., Bidard, F.C., Bardia, A., Kaklamani, V.G., Vlachaki, I., Tonini, G., Habboubi, N., Aftimos, P.G. |
|---|---|
| Zdroj: | In ESMO Open May 2023 8(1) Supplement 4 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|